Praxistätigkeit seit 2018 im Kantonen Glarus, Aargau und Zürich Teilnahme am regionalen Notfalldienst

Sprachen
Deutsch, Englisch, Serbo-Kroatisch, Italienisch

Mitgliedschaften:
FMH (Berufsverband der Schweizer Ärztinnen und Ärzte)
AGZ (Ärztegesellschaft des Kanton Zürich)
VSAO (Verband Schweizerischer Assistenz- und Oberärztinnen und -ärzte)
SGAIM (Schweizerische Gesellschaft für Allgemeine Innere Medizin)

Ausbildung:
2020 Facharzt für Allgemeine Innere Medizin FMH
2018 Staatsexamen Humanmedizin Universität Zürich
2002 Master of Science International Health Management, Health Economies and Health Policy Business School der Bocconi Universität; Milan, Italien
1996 Staatsexamen Humanmedizin Universität Nis-Jugoslawien

Wissenschaftliche Arbeiten:
“Efficacy and safety of octafibrin for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiency” 2011

“A prospective, controlled, randomized, cross-over study investigating the pharmacokinetic properties, surrogate efficacy and safety of Octafibrin compared to Haemocomplettan® P in subjects with congenital fibrinogen deficiency” 2011

“Prospective, Open-Label, Multi-Center, Phase III Clinical Study To Investigate The Efficacy And Safety Of Human Factor VWF/VIII Concentrate (Wilate®) In Subjects With Inherited Type 3 Von Willebrand Disease (VWD) Who Undergo Major Surgical Procedures” 2010

“Surveillance of Results of Long-Term Prophylactic Treatment of von Willebrand Disease with Wilate” 2010

“Evaluation of clinical efficacy, tolerability and immunogenicity in haemophilia A patients under therapy with octanate®” 2009

“Evaluation of clinical efficacy, tolerability and immunogenicity in haemophilia A patients under therapy with wilate®” 2009

“Surveillance of Efficacy and Safety of wilate® in patients with von Willebrand disease” 2009

“Proof of concept study to evaluate the efficacy and safety of Octaplex® plus wilate® for on-demand treatment of spontaneous or trauma induced joint bleeding in patients with severe hemophilia A and inhibitors undergoing prophylactic treatment with octaplex®” 2008

“A feasibility study of the Automated Fluid Shunt for the management of large volume scites” 2008

“The Automated Fluid Shunt in Chronic Congestive Heart Failure” 2008

“Functional evaluation of the NovaShunt Automated Fluid Shunt (AFS) Device in the Canine Model” 2008

“A 6-week, open-label, multi centre study to evaluate the safety of ambulant induction of treatment with lisuride, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s disease and insufficient response to conventional oral therapy” 2007

“Double-blind, placebo-controlled, randomized, multicentre Phase II/ III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy.” 2007

“Lead poisoning; case analyses”, mit Paul Polansky; Nis, Serbien 2005

“Synalar folder-poster”, Grünenthal GmbH; Aachen, Deutschland 2002

“Implementation of quality management in health care services in Western Europe with (ISO, JCAHO, NCQA and EFQM) qualityaccreditation standards”; Comparative study design; Bocconi Universität, Gesundheitsabteilung, – Qualitätsmanagement, Milano, Italien 2001

„Hypertension-Silent Killer“; Gesundheitsinstitut – Nis, Ärzte ohne Grenzen – Griechenland, European Commission Humanitarian Office; Serbien 2000

„Everything you should know about Asthma”; Gesundheitsinstitut – Nis, Ärzte ohne Grenzen – Griechenland, European Commission Humanitarian Office; Serbien 2000

“Artificial abortion in the under-18 age group in Nis”; Klinisches Zentrum Nis; Gesundheitsinstitut, Nis Medizinische Fakultät, Universität Nis; Serbien 1995

Saša Schneider spricht Deutsch, Englisch, Serbo-Kroatisch und Italienisch.